Bone Marrow Transplantation - Table of Contents alert Volume 52 Issue 4

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 52, Issue 4 (April 2017) In this issue Reviews Commentary Original Articles Letters to the Editor Corrigendum Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Reviews Top Sensing danger: toll-like receptors and outcome in allogeneic hematopoietic stem cell transplantation B Kornblit and K Müller Bone Marrow Transplant 2017 52: 499-505; advance online publication, December 12, 2016; 10.1038/bmt.2016.263 Abstract | Full Text Revisiting nutritional support for allogeneic hematologic stem cell transplantation—a systematic review A Baumgartner, A Bargetzi, N Zueger, M Bargetzi, M Medinger, L Bounoure, F Gomes, Z Stanga, B Mueller and P Schuetz Bone Marrow Transplant 2017 52: 506-513; advance online publication, January 9, 2017; 10.1038/bmt.2016.310 Abstract | Full Text Commentary Top Going home for the holidays? Take a shortcut! L Metheny and M de Lima Bone Marrow Transplant 2017 52: 514-515; advance online publication, January 23, 2017; 10.1038/bmt.2016.366 Full Text Original Articles Top ACUTE LEUKEMIA Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience A-L Alloin, G Leverger, J-H Dalle, C Galambrun, Y Bertrand, A Baruchel, A Auvrignon, V Gandemer, C Ragu, A Loundou, C Bilhou-Nabera, M Lafage-Pochitaloff, N Dastugue, B Nelken, C Jubert, F Rialland, G Plat, C Pochon, J-P Vannier, P-S Rohrlich, J Kanold, P Lutz, A Sirvent, C Oudin, W Cuccuini and G Michel on behalf of the ELAM study group Bone Marrow Transplant 2017 52: 516-521; advance online publication, December 12, 2016; 10.1038/bmt.2016.293 Abstract | Full Text Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome S-A Yahng, Y-W Jeon, J-H Yoon, S-H Shin, S-E Lee, Y-S Choi, D-Y Kim, J-H Lee, B-S Cho, K-S Eom, S Lee, C-K Min, H-J Kim, J-W Lee, K-H Lee, W-S Min, J-H Lee and Y-J Kim Bone Marrow Transplant 2017 52: 522-531; advance online publication, November 28, 2016; 10.1038/bmt.2016.295 Abstract | Full Text MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes H Pourhassan, T DeFor, B Trottier, M Dolan, C Brunstein, N Bejanyan, C Ustun and E D Warlick Bone Marrow Transplant 2017 52: 532-538; advance online publication, December 12, 2016; 10.1038/bmt.2016.303 Abstract | Full Text Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML R Duléry, O Nibourel, J Gauthier, V Elsermans, H Behal, V Coiteux, L Magro, A Renneville, A Marceau, T Boyer, B Quesnel, C Preudhomme, A Duhamel and I Yakoub-Agha Bone Marrow Transplant 2017 52: 539-543; advance online publication, January 9, 2017; 10.1038/bmt.2016.318 Abstract | Full Text CHRONIC LEUKEMIA GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses L Sellner, M Brüggemann, M Schlitt, H Knecht, D Herrmann, T Reigl, A Krejci, V Bystry, N Darzentas, M Rieger, S Dietrich, T Luft, A D Ho, M Kneba and P Dreger Bone Marrow Transplant 2017 52: 544-551; advance online publication, December 12, 2016; 10.1038/bmt.2016.305 Abstract | Full Text Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation J Schetelig, L C de Wreede, M van Gelder, N S Andersen, C Moreno, A Vitek, M Karas, M Michallet, M Machaczka, M Gramatzki, D Beelen, J Finke, J Delgado, L Volin, J Passweg, P Dreger, A Henseler, A van Biezen, M Bornhäuser, S O Schönland and N Kröger on behalf of the CLL subcommittee, Chronic Malignancies Working Party Bone Marrow Transplant 2017 52: 552-560; advance online publication, January 23, 2017; 10.1038/bmt.2016.329 Abstract | Full Text LYMPHOMA A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation B M Haverkos, Y Huang, P Elder, L O'Donnell, D Scholl, B Whittaker, S Vasu, S Penza, L A Andritsos, S M Devine and S M Jaglowski Bone Marrow Transplant 2017 52: 561-566; advance online publication, January 9, 2017; 10.1038/bmt.2016.304 Abstract | Full Text PLASMA CELL DISORDERS Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma C Fernández de Larrea, J Dávila, I Isola, E M Ocio, L Rosiñol, R García-Sanz, M T Cibeira, N Tovar, M Rovira, M V Mateos, J S Miguel and J Bladé Bone Marrow Transplant 2017 52: 567-569; advance online publication, November 21, 2016; 10.1038/bmt.2016.299 Abstract | Full Text INHERITED AND GENETIC DISORDERS Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia M S Thakar, C Bonfim, M C Walters, R Storb, R Pasquini, L Burroughs, B M Sandmaier, A Woolfrey and H-P Kiem Bone Marrow Transplant 2017 52: 570-573; advance online publication, January 9, 2017; 10.1038/bmt.2016.301 Abstract | Full Text GRAFT SOURCE A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database N Kurita, M Gosho, Y Yokoyama, T Kato, N Obara, M Sakata-Yanagimoto, Y Hasegawa, N Uchida, S Takahashi, Y Kouzai, Y Atsuta, M Kurata, T Ichinohe and S Chiba Bone Marrow Transplant 2017 52: 574-579; advance online publication, January 9, 2017; 10.1038/bmt.2016.319 Abstract | Full Text CONDITIONING Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients B S Andersson, P F Thall, B C Valdez, D R Milton, G Al-Atrash, J Chen, A Gulbis, D Chu, C Martinez, S Parmar, U Popat, Y Nieto, P Kebriaei, A Alousi, M de Lima, G Rondon, Q H Meng, A Myers, J Kawedia, L L Worth, M Fernandez-Vina, T Madden, E J Shpall, R B Jones and R E Champlin Bone Marrow Transplant 2017 52: 580-587; advance online publication, December 19, 2016; 10.1038/bmt.2016.322 Abstract | Full Text TRANSPLANT TOXICITIES Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management A H Al Jefri, H Abujazar, A Al-Ahmari, A Al Rawas, Z Al Zahrani, A Alhejazi, M A Bekadja, A Ibrahim, M Lahoucine, S Ousia and A Bazarbachi Bone Marrow Transplant 2017 52: 588-591; advance online publication, November 28, 2016; 10.1038/bmt.2016.300 Abstract | Full Text Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT G Battipaglia, M Labopin, A Candoni, R Fanin, J El Cheikh, D Blaise, M Michallet, A Ruggeri, N Contentin, J M Ribera, M Stadler, J Sierra, P A von dem Borne, A Bloor, G Socié, A Nagler and M Mohty Bone Marrow Transplant 2017 52: 592-599; advance online publication, January 16, 2017; 10.1038/bmt.2016.302 Abstract | Full Text Clinical and biological markers of premature aging after autologous SCT in childhood cancer A Vatanen, M Hou, T Huang, O Söder, T Jahnukainen, M Kurimo, T H Ojala, T Sarkola, M Turanlahti, U M Saarinen-Pihkala and K Jahnukainen Bone Marrow Transplant 2017 52: 600-605; advance online publication, January 9, 2017; 10.1038/bmt.2016.334 Abstract | Full Text Letters to the Editor Top Good responses but high TRM in adult patients after MSC therapy for GvHD U Salmenniemi, M Itälä-Remes, J Nystedt, M Putkonen, R Niittyvuopio, K Vettenranta and M Korhonen Bone Marrow Transplant 2017 52: 606-608; advance online publication, December 12, 2016; 10.1038/bmt.2016.317 Full Text Persistent recipient-derived human adenovirus (HAdV) -specific T cells promote HAdV control after allogeneic hematopoietic stem cell transplantation R E Schultze-Florey, S Tischer, W Kühnau, A Heim, B Eiz-Vesper and B Maecker-Kolhoff Bone Marrow Transplant 2017 52: 609-611; advance online publication, January 9, 2017; 10.1038/bmt.2016.321 Full Text Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study E Yokohata, Y Kuwatsuka, H Ohashi, S Terakura, N Kawashima, A Seto, S Kurahashi, Y Ozawa, T Goto, N Imahashi, T Nishida, K Miyao, R Sakemura, T Kato, M Sawa, A Kohno, H Sao, H Iida, H Kiyoi, T Naoe, K Miyamura and M Murata for the Nagoya Blood and Marrow Transplantation Group Bone Marrow Transplant 2017 52: 612-614; advance online publication, January 9, 2017; 10.1038/bmt.2016.323 Full Text Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization D Grosso, E Johnson, B Colombe, O Alpdogan, M Carabasi, J Filicko-O'Hara, S Gaballa, M Kasner, T Klumpp, U Martinez-Outschoorn, J L Wagner, M Weiss, Z Wang and N Flomenberg Bone Marrow Transplant 2017 52: 615-619; advance online publication, January 9, 2017; 10.1038/bmt.2016.324 Full Text Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML F Legrand, A-C Le Floch, A Granata, S Fürst, C Faucher, C Lemarie, S Harbi, S Bramanti, B Calmels, J El-Cheikh, C Chabannon, P-J Weiller, N Vey, L Castagna, D Blaise and R Devillier Bone Marrow Transplant 2017 52: 620-621; advance online publication, December 12, 2016; 10.1038/bmt.2016.326 Full Text Hepatitis E virus infection and hepatic GvHD in allogeneic hematopoietic stem cell transplantation recipients S B Willemse, D L Bezuur, P Blom, E Kneppers, J Verheij, H L Zaaijer and M D Hazenberg Bone Marrow Transplant 2017 52: 622-624; advance online publication, December 19, 2016; 10.1038/bmt.2016.327 Full Text Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant B K Watkins, J Horan, B Storer, P J Martin, P A Carpenter and M E D Flowers Bone Marrow Transplant 2017 52: 625-626; advance online publication, December 19, 2016; 10.1038/bmt.2016.328 Full Text Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors L E Perez, H Fernandez, E Ayala, F Beato, A Neuger, J Pidala, M J Schell and C Anasetti Bone Marrow Transplant 2017 52: 627-629; advance online publication, December 19, 2016; 10.1038/bmt.2016.330 Full Text Pericardial effusion requiring surgical intervention after stem cell transplantation: a case series T M Pfeiffer, S J Rotz, T D Ryan, R Hirsch, M Taylor, R Chima, A Pate, J Hlavaty, M Grimley, K Myers, J El-Bietar, S M Davies, S Jodele and C Dandoy Bone Marrow Transplant 2017 52: 630-633; advance online publication, December 19, 2016; 10.1038/bmt.2016.331 Full Text Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients E G Baraban, S Hu, P Hui, N Podoltsev, D Cooper and M L Xu Bone Marrow Transplant 2017 52: 634-637; advance online publication, December 19, 2016; 10.1038/bmt.2016.332 Full Text Cord blood transplantation, a cost-effective alternative: a health-economic analysis of the National Swedish Cord Blood Bank G Ragnarson Tennvall and A Fasth Bone Marrow Transplant 2017 52: 638-640; advance online publication, December 19, 2016; 10.1038/bmt.2016.333 Full Text Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation C Pittman, M M Hsieh, W Coles, J F Tisdale, N A Weir and C D Fitzhugh Bone Marrow Transplant 2017 52: 641-642; advance online publication, January 9, 2017; 10.1038/bmt.2016.335 Full Text Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation M Carré, A Thiebaut-Bertrand, S Larrat, V Leroy, P Pouzol, N Sturm, S Lhomme, J-Y Cahn, F Garban and P Morand Bone Marrow Transplant 2017 52: 643-645; advance online publication, January 9, 2017; 10.1038/bmt.2016.337 Full Text Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation J S Stenehjem, K B Smeland, K Murbraech, H Holte, S Kvaløy, T Wethal, C E Kiserud and M B Lund Bone Marrow Transplant 2017 52: 646-649; advance online publication, December 19, 2016; 10.1038/bmt.2016.338 Full Text Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience J Meissner, H Finel, S Dietrich, A Boumendil, E Kanfer, G Laboure, M Abecasis, J Cornelissen, J Delage, J Finke, U Hess, H Ludwig, M Mohty, T Pabst, P Pioltelli, S Robinson, P Samaras, S Montoto and P Dreger Bone Marrow Transplant 2017 52: 650-652; advance online publication, December 19, 2016; 10.1038/bmt.2016.339 Full Text Successful haploidentical BMT with post-transplant cyclophosphamide for refractory autoimmune pancytopenia after cord blood transplant in pediatric myelodysplastic syndrome H Shima, K Isshiki, Y Yamada, F Yamazaki, T Takahashi and H Shimada Bone Marrow Transplant 2017 52: 653-655; advance online publication, January 9, 2017; 10.1038/bmt.2016.341 Full Text Corrigendum Top GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses L Sellner, M Brüggemann, M Schlitt, H Knecht, D Herrmann, T Reigl, A Krejci, V Bystry, N Darzentas, M Rieger, S Dietrich, T Luft, A D Ho, M Kneba and P Dreger Bone Marrow Transplant 2017 52: 656; 10.1038/bmt.2017.12 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Bone Marrow Transplantation. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.